Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ORTX Orchard Therapeutics

0.477
-0.009-1.85%
Close 09/29 16:00 ET
High
0.490
Open
0.480
Turnover
42.60K
Low
0.470
Pre Close
0.486
Volume
88.57K
Market Cap
60.30M
P/E(TTM)
Loss
52wk High
2.230
Shares
126.46M
P/E(Static)
Loss
52wk Low
0.412
Float Cap
38.00M
Bid/Ask %
60.00%
Historical High
21.640
Shs Float
79.69M
Volume Ratio
0.19
Historical Low
0.412
Dividend TTM
--
Div Yield TTM
--
P/B
0.41
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.11%
Amplitude
4.02%
Avg Price
0.481
Lot Size
1
Float Cap
38.00M
Bid/Ask %
60.00%
Historical High
21.640
Shs Float
79.69M
Volume Ratio
0.19
Historical Low
0.412
Dividend TTM
--
P/B
0.41
Dividend LFY
--
Turnover Ratio
0.11%
Amplitude
4.02%
Avg Price
0.481
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.
CEO: Dr. Hubert Gaspar
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...